Viracta Therapeutics, Inc. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - March 31, 2010

Attached files

file filename
10-K - FORM 10-K - Viracta Therapeutics, Inc.d10k.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) OR 15D-14(A) - Viracta Therapeutics, Inc.dex312.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) OR 15D-14(A) - Viracta Therapeutics, Inc.dex311.htm
EX-32.1 - CERTIFICATION OF CEO & CFO PURSUANT TO 13A-14(B) OR 15D-14(B) - Viracta Therapeutics, Inc.dex321.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-164025) and related Prospectus, and the Registration Statements on Forms S-8 (Nos. 333-128647, 333-132679, 333-138758, 333-145404, 333-150834 and 333-160528) pertaining to the 1998 Stock Plan, 2001 Stock Plan, 2005 Equity Incentive Award Plan, Amended and Restated 2006 Employment Commencement Incentive Plan and Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc., of our report dated March 31, 2010, with respect to the financial statements of Sunesis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2009.

/s/ Ernst & Young LLP

Palo Alto, California

March 31, 2010

 

Stock widget

Investing forum

Viracta Therapeutics, Inc. Reports